{"certainty":[{"description":"Moderate certainty due to risk of bias","rating":{"coding":[{"code":"moderate","display":"Moderate quality","system":"http://hl7.org/fhir/certainty-rating"}]},"subcomponent":[{"rating":{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]},"type":{"coding":[{"code":"PublicationBias","display":"Publication bias","system":"http://hl7.org/fhir/certainty-type"}]}},{"rating":{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]},"type":{"coding":[{"code":"Inconsistency","display":"Inconsistency","system":"http://hl7.org/fhir/certainty-type"}]}},{"rating":{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]},"type":{"coding":[{"code":"Imprecision","display":"Imprecision","system":"http://hl7.org/fhir/certainty-type"}]}},{"rating":{"coding":[{"code":"no-concern","display":"no serious concern","system":"http://hl7.org/fhir/certainty-rating"}]},"type":{"coding":[{"code":"Indirectness","display":"Indirectness","system":"http://hl7.org/fhir/certainty-type"}]}},{"note":[{"text":"results largely influenced by IST-3 trial which was unblinded and NINDS trial which had allocation concealment not stated and baseline imbalances"}],"rating":{"coding":[{"code":"serious-concern","display":"serious concern","system":"http://hl7.org/fhir/certainty-rating"}]},"type":{"coding":[{"code":"RiskOfBias","display":"Risk of bias","system":"http://hl7.org/fhir/certainty-type"}]}}],"type":{"coding":[{"code":"Overall","display":"Overall certainty","system":"http://hl7.org/fhir/certainty-type"}]}}],"contact":[{"telecom":[{"system":"url"}]}],"description":"mRS 3-6 at 90 days Odds Ratio 0.65 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 0-3 hours prior","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"id":"example-stroke-0-3-alteplase-vs-no-alteplase-mRS3-6","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.5"}],"name":"EffectOfAlteplaseVsNoAlteplaseOnMRS36At90DaysInStroke03HoursPrior","publisher":"HL7 International / Clinical Decision Support","relatedArtifact":[{"citation":"Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29(7):CD000213. PMID 25072528","display":"Analysis 1.16 from Wardlaw 2014","document":{"url":"https://doi.org/10.1002/14651858.CD000213.pub3"},"label":"Wardlaw 2014","type":"citation"}],"resourceType":"Evidence","statistic":[{"attributeEstimate":[{"description":"95% CI 0.54 to 0.80","level":0.95,"range":{"high":{"value":0.8},"low":{"value":0.54}},"type":{"coding":[{"code":"C53324","display":"Confidence interval","system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type"}]}},{"description":"P-value = 0.000023","quantity":{"value":0.000023},"type":{"coding":[{"code":"C44185","display":"P-value","system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type"}]}},{"description":"Heterogeneity I-sq = 0.0%","quantity":{"code":"%","system":"http://unitsofmeasure.org","unit":"%","value":0},"type":{"coding":[{"code":"0000420","display":"I-squared","system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type"}]}}],"numberOfEvents":1137,"quantity":{"value":0.65},"sampleSize":{"numberOfParticipants":1779,"numberOfStudies":6},"statisticType":{"coding":[{"code":"C16932","display":"Odds Ratio","system":"http://terminology.hl7.org/CodeSystem/statistic-type"}]}}],"status":"draft","studyDesign":[{"coding":[{"code":"SEVCO:01003","display":"randomized assignment","system":"http://hl7.org/fhir/study-design"}]}],"synthesisType":{"coding":[{"code":"std-MA","display":"summary data meta-analysis","system":"http://terminology.hl7.org/CodeSystem/synthesis-type"}]},"text":{"div":"
\n "Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior" is a comparative effect estimate.\n
\n\t\n